Minimal residual disease (MRD) testing, based on the detection of circulating tumor DNA (ctDNA), is gaining traction as a highly sensitive and accurate method for longitudinal cancer monitoring. Successful detection of ctDNA requires high analytical sensitivity because this analyte is typically present at extremely low concentrations in patient samples. While next-generation sequencing (NGS) is the gold-standard detection method in many settings, digital PCR (dPCR) is increasingly used for rapid, cost-effective monitoring of known targets in both solid tumors and hematological malignancies. In this presentation, we examine the utility of both NGS and dPCR for MRD testing and reveal how these two approaches complement one another. We discuss how dPCR provides a rapid, scalable and cost-efficient complement to existing molecular methods, with the potential to enable faster clinical decisions and improve patient management.